Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

OBJECTIVE Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently
approved antihyperglycemic medications. We sought to describe their association with …

US Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2
inhibitors for diabetes may result in a serious condition of too much acid in the blood …

OBJECTIVE To evaluate the safety and efficacy of empagliflozin 10-and 25-mg doses plus a
unique lower dose (2.5 mg) as adjunct to intensified insulin in patients with type 1 diabetes …

Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications
shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood …

Context: Sodium glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic drugs that
increase urinary excretion of glucose, thereby improving glycemic control and promoting …

Inhibitors of sodium–glucose co-transporter type 2 (SGLT2) are proposed as a novel
approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are …

Sodium-glucose cotransporter-2 (SGLT2) is selectively expressed in the human kidney,
where it executes reabsorption of filtered glucose with a high capacity; it may be overactive …

Purpose Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of
antihyperglycemic agents available on the market. Regulator warnings and concerns …